Total Payments
$2.1M
2024 Payments
$339,761
Companies
29
Transactions
1,728
Medicare Patients
1,400
Medicare Billing
$422,401
Payment Breakdown by Category
Other$1.6M (78.4%)
Travel$280,413 (13.6%)
Consulting$129,312 (6.3%)
Food & Beverage$31,077 (1.5%)
Research$3,200 (0.2%)
Education$217.42 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 503 | 74.9% |
| Travel and Lodging | $280,413 | 726 | 13.6% |
| Consulting Fee | $129,312 | 59 | 6.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $70,615 | 21 | 3.4% |
| Food and Beverage | $31,077 | 411 | 1.5% |
| Unspecified | $3,200 | 1 | 0.2% |
| Honoraria | $1,980 | 1 | 0.1% |
| Education | $217.42 | 6 | 0.0% |
Payments by Type
General
$2.1M
1,727 transactions
Research
$3,200
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $223,035 | 185 | $0 (2024) |
| Janssen Biotech, Inc. | $215,461 | 196 | $0 (2024) |
| PFIZER INC. | $208,088 | 138 | $0 (2024) |
| Exelixis Inc. | $193,660 | 225 | $0 (2024) |
| Astellas Pharma US Inc | $164,484 | 134 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $139,496 | 120 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $133,340 | 87 | $0 (2024) |
| GENZYME CORPORATION | $117,430 | 82 | $0 (2022) |
| Eisai Inc. | $113,466 | 89 | $0 (2024) |
| Amgen Inc. | $95,083 | 125 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $339,761 | 283 | Merck Sharp & Dohme LLC ($66,983) |
| 2023 | $337,701 | 280 | AstraZeneca Pharmaceuticals LP ($56,754) |
| 2022 | $238,719 | 177 | EMD Serono, Inc. ($35,724) |
| 2021 | $180,947 | 109 | PFIZER INC. ($37,100) |
| 2020 | $111,409 | 93 | Astellas Pharma US Inc ($24,626) |
| 2019 | $253,431 | 202 | Janssen Biotech, Inc. ($71,576) |
| 2018 | $314,636 | 295 | Janssen Scientific Affairs, LLC ($110,409) |
| 2017 | $279,186 | 289 | Genentech USA, Inc. ($56,396) |
All Payment Transactions
1,728 individual payment records from CMS Open Payments — Page 1 of 70
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $6.78 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,132.00 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Exelixis Inc. | CABOMETYX (Drug) | Consulting Fee | Cash or cash equivalent | $7,920.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/26/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,590.00 | General |
| Category: HORMONE THERAPY | ||||||
| 11/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $3,456.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Travel and Lodging | In-kind items and services | $527.23 | General |
| Category: HORMONE THERAPY | ||||||
| 11/25/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Travel and Lodging | Cash or cash equivalent | $130.69 | General |
| Category: HORMONE THERAPY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Travel and Lodging | In-kind items and services | $192.24 | General |
| Category: HORMONE THERAPY | ||||||
| 11/18/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $114.05 | General |
| Category: HORMONE THERAPY | ||||||
| 11/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $645.98 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $437.95 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $424.82 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $128.36 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/15/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $49.38 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/15/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $44.29 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/15/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $26.92 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/15/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $3.69 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | Cash or cash equivalent | $40.91 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $1,683.80 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PADCEV CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 401 | 1,165 | $337,860 | $107,646 |
| 2022 | 5 | 324 | 1,067 | $312,615 | $112,833 |
| 2021 | 5 | 335 | 1,135 | $322,138 | $118,233 |
| 2020 | 4 | 340 | 1,069 | $295,184 | $83,689 |
Total Patients
1,400
Total Services
4,436
Medicare Billing
$422,401
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 191 | 722 | $184,291 | $56,240 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 86 | 309 | $106,924 | $36,919 | 34.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 75 | 75 | $36,667 | $11,664 | 31.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 16 | 16 | $3,920 | $1,348 | 34.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 22 | 30 | $2,535 | $813.85 | 32.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 13 | $3,523 | $661.75 | 18.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 149 | 497 | $124,747 | $40,926 | 32.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 57 | 266 | $89,908 | $32,467 | 36.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 103 | $36,359 | $16,937 | 46.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 38 | 134 | $35,490 | $13,758 | 38.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 38 | 38 | $18,333 | $5,802 | 31.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $5,346 | $1,963 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 18 | $2,432 | $979.54 | 40.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 148 | 581 | $146,061 | $48,200 | 33.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 63 | 273 | $92,274 | $34,718 | 37.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 40 | 134 | $35,242 | $15,032 | 42.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 19 | 74 | $26,122 | $12,288 | 47.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 29 | 29 | $13,949 | $4,891 | 35.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 17 | 21 | $5,523 | $1,836 | 33.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 23 | $2,967 | $1,268 | 42.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 153 | 604 | $151,784 | $39,261 | 25.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 54 | 194 | $65,617 | $18,125 | 27.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 54 | 162 | $42,606 | $15,263 | 35.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 38 | 38 | $18,300 | $5,233 | 28.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 15 | 34 | $12,002 | $4,333 | 36.1% |
About Dr. Nancy Dawson, M.D
Dr. Nancy Dawson, M.D is a Medical Oncology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073571519.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nancy Dawson, M.D has received a total of $2.1M in payments from pharmaceutical and medical device companies, with $339,761 received in 2024. These payments were reported across 1,728 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Dawson has provided services to 1,400 Medicare beneficiaries, totaling 4,436 services with total Medicare billing of $422,401. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Washington, DC
- Active Since 05/03/2006
- Last Updated 03/20/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1073571519
Products in Payments
- KEYTRUDA (Biological) $192,765
- Erleada (Drug) $188,545
- XTANDI (Drug) $147,175
- ERLEADA (Drug) $131,100
- LYNPARZA (Drug) $126,605
- JEVTANA (Drug) $117,430
- Lenvima (Drug) $113,403
- ORGOVYX (Drug) $111,394
- CABOMETYX (Drug) $103,317
- Cabometyx (Drug) $90,342
- PADCEV (Biological) $81,368
- Nubeqa (Drug) $73,991
- TECENTRIQ (Biological) $69,198
- XGEVA (Biological) $65,628
- Xtandi (Drug) $61,580
- BAVENCIO (Drug) $45,527
- Bavencio (Drug) $35,724
- Padcev (Drug) $33,607
- LYNPARZA (Biological) $30,270
- PYLARIFY (Drug) $29,159
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Washington
Dr. Pashna Munshi, M.d, M.D
Medical Oncology — Payments: $181,342
Medical Oncology $181,342
Dr. Khaled El-Shami, Md, MD
Medical Oncology — Payments: $87,325
Medical Oncology $87,325
Dr. Mitchell Smith, M.d, M.D
Medical Oncology — Payments: $66,826
Medical Oncology $66,826
Dr. Channing Paller, M.d, M.D
Medical Oncology — Payments: $35,482
Medical Oncology $35,482
Maria Nunes, Md, MD
Medical Oncology — Payments: $26,005
Medical Oncology $26,005
Giampaolo Talamo, Md, MD
Medical Oncology — Payments: $18,208
Medical Oncology $18,208